TD Cowen analyst Tyler Van Buren has reiterated their bullish stance on ACLX stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Arcellx Inc’s promising developments. The imminent BLA filing for Anito-cel, expected to launch by mid-to-late 2026, is a significant milestone. The clinical profile of Anito-cel, coupled with the partnership with Kite, suggests a rapid approval process. Importantly, the ASH data indicates a clean safety profile with no delayed neurotoxicity or colitis, enhancing investor confidence.
Furthermore, the recent pre-BLA meeting with the FDA was positive, aligning with previous interactions and suggesting a smooth path forward. The quick receipt of meeting minutes was an encouraging sign, and with the potential for priority review, a commercial launch in mid-to-late 2026 is highly anticipated. If approval is secured without any Parkinsonism events, Anito-cel could maintain its competitive safety advantage, bolstering its market launch prospects. These factors collectively underpin the Buy rating for Arcellx Inc.